It had posted net profit of Rs 32.54 crore for the April-June period of 2013-14 fiscal, Ajanta Pharma said in a filing to BSE.
Standalone total income from operations of the company in Q1, 2014-15 rose to Rs 287.49 crore, as against Rs 218.19 crore in the year-ago period.
"The Q1 performance reflects our ability to deliver consistent results by maintaining our focus on select therapeutic specialities and geographies," Ajanta Pharma MD Yogesh M Agrawal said.
Exports contributed 56 per cent of the revenue for the quarter, Ajanta Pharma said.
Shares of Ajanta Pharma were trading at Rs 1,590.75 per scrip in the afternoon trade on BSE, down 8.60 per cent from the previous close.